Welcome to our dedicated page for Lineage Cell The news (Ticker: LCTX), a resource for investors and traders seeking the latest updates and insights on Lineage Cell The stock.
Lineage Cell Therapeutics, Inc. (LCTX) generates a steady flow of news as a clinical-stage biotechnology company developing allogeneic, or “off the shelf,” cell therapies for serious medical conditions. News updates commonly highlight progress across its proprietary cell-based technology platform, clinical programs, manufacturing capabilities, and strategic collaborations.
Investors following LCTX news can expect coverage of clinical milestones from its lead programs, including OpRegen retinal pigment epithelial cell therapy for geographic atrophy secondary to age-related macular degeneration and OPC1 oligodendrocyte progenitor cell therapy for spinal cord injuries. Company announcements often describe data presentations from ongoing studies, such as long-term follow-up results from the OpRegen Phase 1/2a trial and updates from the GAlette Phase 2a study, as well as developments in the DOSED clinical study evaluating a novel delivery system for OPC1 in subacute and chronic spinal cord injury.
Lineage’s news flow also features preclinical and platform updates, including progress with ReSonance (ANP1), an auditory neuronal progenitor cell program for hearing loss under a research collaboration with William Demant Invest A/S, and initiatives such as PNC1 for potential treatment of vision loss and ILT1, an islet cell transplant program for Type 1 Diabetes. Additional releases may cover advances in its AlloSCOPE manufacturing platform, cGMP production runs from its two-tiered cell banking system, and gene-editing collaborations involving the RND1 hypoimmune induced pluripotent stem cell line.
Corporate news items include quarterly financial results, capital-raising transactions, and governance matters disclosed through press releases and SEC filings. For investors and observers interested in the evolution of allogeneic cell transplantation, the LCTX news page provides ongoing insight into Lineage’s clinical data, research collaborations, manufacturing achievements, and strategic direction.
Lineage Cell Therapeutics (NYSE American/TASE: LCTX) will report first quarter 2026 financial and operating results on May 12, 2026 after U.S. market close and will host a conference call and webcast at 4:30 p.m. ET / 1:30 p.m. PT the same day to provide a business update.
Dial-in, conference ID, live webcast and replay details will be available via the company’s investors website; a telephone replay will be available through May 19, 2026.
Lineage (NYSE American: LCTX) reported 36-month Phase 1/2a data for RG6501 (OpRegen) in geographic atrophy (GA). Cohort 4 treated eyes (n=10) showed mean BCVA +6.2 ETDRS letters at 36 months; a subgroup with extensive bleb coverage (n=5) showed +9.0 letters. Quantitative OCT showed sustained RPE-C and ELM structural improvements versus fellow eyes through 36 months after a single subretinal administration. The GAlette surgical optimization Phase 2a study is enrolling to refine delivery methods and devices.
Lineage (NYSE American: LCTX) on April 13, 2026 announced formation of a Scientific Advisory Board (SAB) with Joachim Fruebis, Ph.D., as founding member, and appointed Priyantha Herath, M.D., Ph.D., as Senior Vice President and Head of Clinical Operations. The SAB will advise development of Lineage’s AlloSCOPE™ allogeneic cell transplant pipeline; additional members are expected later in 2026.
The appointments emphasize cross-therapeutic expertise in ophthalmology, neurology, and translational clinical development to support preclinical and clinical advancement of the company’s cell therapy programs.
Lineage (NYSE: LCTX) launched COR1, a new internally developed corneal endothelial cell (CEnC) therapy program in preclinical development for corneal endothelial disease, including Fuchs Endothelial Corneal Dystrophy and bullous keratopathy. Lineage reports manufacturing of off-the-shelf CEnCs that meet initial internal identity, morphological, and functional criteria using its AlloSCOPE platform.
The company cites donor shortages (one donor per 70 diseased eyes) and aims to leverage AlloSCOPE and a proprietary pluripotent cell line to scale production and potentially reduce costs via its AlloSCOPE “5D” process.
Lineage Cell Therapeutics (NYSE: LCTX) reported Q4 and full‑year 2025 results and a business update highlighting clinical, manufacturing, and collaboration milestones. Key points include achieving the first milestone under the Roche/Genentech collaboration, positive 36‑month OpRegen data, a WDI research pact up to $12M, expanded AlloSCOPE manufacturing capability, and cash of $55.8M expected to support operations into Q2 2028.
Lineage Cell Therapeutics (NYSE American: LCTX) will report fourth quarter and full year 2025 financial and operating results on March 5, 2026 after U.S. market close. Management will host a conference call and webcast the same day at 4:30 p.m. ET / 1:30 p.m. PT to provide a business update.
Dial-in access and a live webcast will be available; a webcast replay will remain online for 30 days and a telephone replay will be available through March 12, 2026 using the provided conference ID.
Lineage (NYSE American: LCTX) received a novel gene-edited induced pluripotent stem cell (iPSC) line from Factor Bioscience on Jan 6, 2026 under their existing collaboration.
The hypoimmune line includes a targeted deletion of B2M, targeted insertion/overexpression of HLA-E, and a third undisclosed disease-specific edit. Acceptance triggered a success payment to Factor; an additional payment is contingent on Lineage taking an exclusive license. Lineage will further test the line for performance and compatibility with its AlloSCOPE manufacturing platform before deciding to license and advance programs.
Lineage Cell Therapeutics (NYSE American: LCTX) published a January 5, 2026 letter highlighting 2025 achievements and 2026 priorities. Key points include progress in the partnered OpRegen program for geographic atrophy (single-dose visual improvement reported lasting at least 3 years), Genentech opened 9 additional sites and obtained RMAT designation for OpRegen, receipt of the company’s first cash milestone toward up to $620 million in partner milestones, advancement of the proprietary AlloSCOPE manufacturing platform (two cGMP runs and a clinic-released product), a new ReSonance collaboration, a William Demant partnership, and launch of an islet cell initiative for Type 1 Diabetes.
Priorities for 2026: clinical readouts and milestones, manufacturing expansion, selective partnerships, and disciplined capital allocation.
Lineage Cell Therapeutics (NYSE: LCTX) reported Q3 2025 results and a business update on November 6, 2025. Key items: a research collaboration with William Demant Invest providing up to $12 million for preclinical development of ReSonance (ANP1); cGMP production runs for OpRegen and OPC1 from a two-tier cell bank process enabling potential production of millions of doses; positive 36-month Phase 1/2a OpRegen clinical results featured at CTS 2025; first chronic spinal cord injury participant treated with OPC1 in the DOSED study with no significant safety events at 60 days. Financials: cash and marketable securities $40.5M as of Sept 30, 2025 (runway into Q2 2027) and Q3 net loss $29.8M ($0.13/sh), driven largely by a $26.6M non-cash fair value remeasurement of warrant liabilities.
Lineage Cell Therapeutics (NYSE American: LCTX) will report its third quarter 2025 financial and operating results on Thursday, November 6, 2025 after U.S. market close. Management will host a conference call and live webcast on November 6, 2025 at 4:30 p.m. ET / 1:30 p.m. PT to discuss results and provide a business update.
Dial-in for the call from the U.S. and Canada is (888) 596-4144 (request “Lineage Cell Therapeutics Call”). A live webcast will be available in the Investors section of Lineage’s website. Webcast replay will be available on the website for 30 days, and a telephone replay is available through November 14, 2025 at (800) 770-2030 using conference ID 3958367.